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Abstract The bcl-2 gene is an important antagonist of 
apoptosis, the programmed cell death. Bcl-2 is highly expressed 
in a variety of lymphomas. Lymphocytes of patients with chronic 
lymphocytic leukemia (CLL) express high amounts of bcl-2 even 
in the absence of the t(14; 18) translocation, resulting in a strong 
resistance towards corticosteroid induced apoptosis. Within the 
5'-untranslated region of the bcl-2 gene a p53 dependent negative 
response element has been described. Genetic alterations within 
this element could lead to uncontrolled overexpression of bcl-2 
and subsequent resistance towards apoptosis. We therefore 
analyzed the mRNA from the 5'-untranslated region —279 to 
—85 bp of the bcl-2 gene by direct PCR sequencing from 
peripheral blood derived lymphocytes from patients with CLL 
and normal healthy donors. Compared to published sequences 
(Tsujimoto and Croce (1986) Proc. Natl. Acad. Sci. USA 83, 
5214), we consistently found an exchange at position 1271 from 
A to G and at position 1284 from G to A in all CLL as well as 
normal donor derived samples analyzed. Thus, CLL specific 
alterations compared to normal cells could not be found and 
deregulated expression of bcl-2 in CLL cells does not appear to 
be due to alterations in the p53 dependent negative response 
element of the bcl-2 gene. However, our data add information to 
published sequence data of this region. 
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1. Introduction 
bcl-2 is an important regulator of cell death [1]. Overexpres-
sion has been found originally in the context of t( 14; 18) trans-
locations in follicular lymphoma [2,3]. However, high levels of 
bcl-2 are found even in the absence of t(14;18) in a variety of 
lymphoma tissues [4-6] as well as normal tissue progenitors 
[7,8]. Lymphocytes from patients with chronic lymphocytic 
leukemia (CLL) express high amounts of bcl-2, although a 
t(14;18) is not present in this disease entity [9]. Furthermore, 
CLL cells are resistant towards induction of apoptosis, e.g. 
with corticosteroids [10]. 
Recently, a negative regulatory element (NRE) in the 5'-
untranslated region of bcl-2 has been described [11]. This el-
ement inhibits expression from an upstream promoter and is 
responsive to the effects of p53 [12]. Experimentally induced 
mutations within this untranslated region corresponding to 
position —279 to —85 bp of the bcl-2 gene abolish the effect 
of the NRE leading to uncontrolled overexpression of bcl-2. 
The aim of our study was the analysis of CLL cells in order 
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to look for mutations within this part of the bcl-2 gene in 
correlation with a specific state of disease. By using direct 
PCR amplification we found sequence variations compared 
to published data. However, base pair exchanges were consis-
tently found in CLL as well as normal cells. 
2. Material and methods 
Peripheral blood mononuclear cells (PBMNCs) were obtained from 
healthy normal donors and patients with CLL, as leftovers from di-
agnostic samples. CLL patients presented with various stages of dis-
ease (RAI I-IV). PBMNCs were prepared after Ficoll centrifugation 
and were frozen at —80°C. 
2.1. RNA extraction, cDNA preparation and PCR 
Extraction of RNA was performed using a guanidinium-isothiocya-
nate and phenol based method with a commercially available kit 
(Ultraspec RNA Isolation System, Campro Sci.) followed by DNase 
digestion (RQ1 RNase-free DNase, Promega). 20 ul DNase was used 
in a total volume of 200 j_il for 30 min at 37°C followed by phenol/ 
chloroform extraction and ethanol precipitation. 3 ug RNA was tran-
scribed into cDNA using Superscript RNase H-Reverse Transcriptase 
(Gibco BRL) for 10 min at 23°C, 60 min at 45°C, and 5 min at 95°C. 
PCR amplification of cDNA was performed using the GeneAmp PCR 
Reagent Kit with AmpliTaq DNA Polymerase (Perkin Elmer) and 
FPLC purified primers. In 50 ul final volume 0.4 ul of AmpliTaq 
Polymerase (5 U/ul) 30 pmol primer each and 1% DMSO were used 
for the amplification of a 194 bp large fragment corresponding to 
position -279 to -85 5' of the bcl-2 gene. Primer bcl-2-219S (5'A-
CAGAGGAAG TAGACTGATA TTAAC) and bcl-2-85A (5'A-
GAGGAGTTA TAATCCAGCT ATTT) [12] were used with an an-
nealing temperature of 63°C for 35 cycles. For the quality control of 
cDNA the housekeeping gene PBGD was used [5]. 
2.2. PCR sequencing 
PCR fragments were separated in a 2% agarose gel and after stain-
ing with ethidium bromide bands were cut out and the DNA was 
extracted using a kit (QIAquick, QIAgen). Direct sequencing using 
33p end labeling was performed with a SequiTherm Cycle Sequencing 
Kit (Biozym). Each probe was analyzed twice and in sense and anti-
sense directions. Sequences were read into a computer program 
(DNASIS) and compared to published sequences [13,14]. 
3. Results and discussion 
Samples from 15 patients with CLL and two healthy nor-
mal donors were analyzed. By repeating the sequencing anal-
ysis at least once using the sense and antisense primers, re-
spectively, the sequence from position —279 to —85 of the 5'-
untranslated region of bcl-2 for nine individual patients could 
be read reliably and only fully interpretable unequivocal data 
were used for the final analysis. In six patients the RNA was 
of poor quality not allowing reliable sequence analysis. No 
major deletions were found within this region. However, in 
all the other nine CLL and in both normal donor samples 
adenine was substituted for guanine at position 1271 of the 
bcl-2 mRNA and guanine was substituted for adenine at po-
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Fig. 1. Direct PCR sequencing using sense (A) or antisense (B) pri-
mer from CLL patient No. 15 (A) and normal donor No. 2 (B). 
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sition 1284 (Fig. 1). No other consistent sequence deviation 
compared to Tsujimoto et al. [13] was detected. 
The finding of a negative regulatory element in the 5'-un-
translated region of the bcl-2 gene which is responsive to p53 
is of major interest. The relevance for a specific state of dis-
ease, however, has not been documented so far. In our at-
tempt to look for genetic abnormalities in lymphoma cells of 
patients with CLL we found two sequence deviations com-
pared to Tsujimoto et al. [13]. However, analysis of PBMNC 
from healthy donors showed the same base substitutes. There-
fore these changes can not be regarded as disease specific. The 
complete mRNA sequence including the 5'-untranslated re-
gion has been published by two groups [13,14]. Within the 
region of the NRE Seto et al. [14] showed several base sub-
stitutes compared to the sequence published by Tsujimoto and 
Croce. We can confirm the exchanges at positions 1271 and 
1285, but did not find any other sequence deviations from the 
data of Tsujimoto and Croce [13]. 
In conclusion, within the p53 dependent negative response 
element 5' to the bcl-2 gene two base pair exchanges were 
found in comparison to the reference sequence [13]. Thus, 
no disease specific changes in this area could be seen in sam-
ples from patients in CLL and other causes may contribute to 
the high levels of bcl-2 expression in chronic lymphocytic leu-
kemia. 
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